Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:359
Structure:
Synonyms:
1,3,5-Benzenetriol
1,3,5-Benzenetriol, dihydrate
1,3,5-THB
1,3,5-Trihydroxybenzene
1,3,5-Trihydroxybenzene anhydrous
1,3,5-Trihydroxybenzene dihydrate
1,3,5-Trihydroxycyclohexatriene
1,3,5-Triol
108-73-6
3,5-Dihydroxyphenol
4-06-00-07361 (Beilstein Handbook Reference)
5-Benzenetriol
5-Hydroxyresorcinol
5-Oxyresorcinol
5-Oxyresorcinolphloroglucin
6099-90-7
626-71-1
79330_ALDRICH
79330_FLUKA
AB1004109
AC1L192D
AC1Q1GOU
AG-D-25303
AI3-08848
AIDS-017800
AIDS017800
AKOS000119851
AR-1B6233
BB_NC-2225
Benzene, 1,3,5-trihydroxy-
Benzene, trihydroxy
Benzene-1,3,5-triol
Benzene-s-triol
BRN 1341907
c0026
C02183
C6H6O3
CCRIS 4147
CHEBI:16204
CHEMBL473159
CPD-16
D00152
Dilospan S
Dilospan S (TN)
EINECS 203-611-2
Floroglucin
Floroglucin [Czech]
Floroglucinol
Floroglucinol [Czech]
I04-0078
KST-1B6373
LS-105905
MolPort-000-871-966
NCGC00166270-01
NSC 1572
NSC1572
P0249
P1178_SIGMA
P1376
P3502_SIAL
P38005_ALDRICH
Phloroglucin
Phloroglucine
Phloroglucinol
Phloroglucinol (JAN)
Phloroglucinol dihydrate
s-Trihydroxybenzene
Spasfon-Lyoc
ST5214381
sym-Trihydroxybenzene
TL8000285
WLN: QR CQ EQ
ZINC00391883
ATC-Codes:

Target

show target details
Uniprot ID:Q9Y354_HUMAN
Synonyms:
Matrix metalloproteinase 9
EC-Numbers:3.4.24.35
Organism:Homo sapiens
Human
PDB IDs:-

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

16467866
Hyperforin inhibits MMP-9 secretion by B-CLL cells and microtubule formation by endothelial cells.. C Quiney; C Billard; P Mirshahi; J-D Fourneron; J-P Kolb (2006) Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K display abstract
We previously reported that hyperforin (HF), a natural phloroglucinol purified from Saint John's wort, can induce the apoptosis of leukemic cells from patients with B-cell lymphocytic leukemia (B-CLL) ex vivo. We show here that treatment of cultured B-CLL patients' cells with HF results in a marked inhibition of their capacity to secrete matrix metalloproteinase-9, an essential component in neo-angiogenesis through degradation of the extracellular matrix process. The phloroglucinol acts by decreasing the production of the latent 92 kDa pro-enzyme. The inhibitory effect of HF is associated with a decrease in VEGF release by the leukemic cells. Moreover, HF is found to prevent the formation of microtubules by human bone marrow endothelial cells cultured on Matrigel, evidencing its capacity to inhibit vessel formation. Our results show the antiangiogenesis activity of HF and strengthen its potential interest in the therapy of B-CLL.